- Quick & Easy: Simple 20 minute procedure.
- Highest Yield: Recover 3x more DNA.
- Ultra-Pure: Ready for qPCR, Next-Gen Sequencing, arrays, etc.
|Elution Volume||≤ 35 µl|
|Equipment||Water bath or heat block (55°C), microcentrifuge, and vortex.|
|Purity||High quality DNA is ready for all sensitive downstream applications such as PCR, endonuclease digestion, Southern blotting, genotyping, Next-Gen sequencing, bisulfite conversion, etc. (A260/A230≥ 2.0).|
|Size Range||Capable of recovering genomic and mitochondrial DNA sized fragments > 50 kb. If present, parasitic, microbial, and viral DNA will also be recovered.|
|Workflow||Utilize a Proteinase K Digestion and Zymo-Spin Column for effective recovery of DNA.|
|Yield||The DNA binding capacity of the column is 25 µg. Typically, mammalian tissues yield: 1-3 µg DNA per mg skeletal, heart, lung, and brain tissues and 3-5 µg DNA per mg liver and kidney. Human whole blood will yield 3-7 µg DNA per 100 µl blood sampled.|
Q1: What is the difference between the digestion buffers? Can one buffer be used for all sample types?
Q2: What is the difference between Quick-DNA and Quick-DNA Plus kits?
Q3: Can Proteinase K digestion be performed overnight in DNA/RNA Shield?
Q4: I’m seeing some yield inconsistencies with my blood samples, what’s happening?
Q5: Can the Quick-DNA Plus kit be used with bacterial samples?
Q6: Can I use Quick-DNA Plus to clean-up previously isolated DNA?
Q7: What is the purpose of adding beta-mercaptoethanol? Can this step be substituted or omitted?
Q8: Can Quick-DNA process crude lysates?
Q9: What are the expected yields for each sample type?
LAM is a rare low-grade metastasizing lung neoplasm. Inhibitors of mTOR improve clinical outcome of LAM patients by preventing loss of lung function. Nevertheless, other cell targets may be of interest for drug development. Therefore, we explored the potential role of EDN1 (endothelin) in LAM. We report an increased endothelin blood level in LAM patients as well as EDN1 overexpression and EDN1 receptor downregulation in LAM-derived primary cells and in TSC2NEG cells mutated in TSC2. We evidenced EDN pathway dysregulation based on EDN1, EDNRA, EDNRB and ARRB1 mRNA expression in LAM-derived primary cells. We showed overexpression of EDN1 and ARRB1 mRNAs in TSC2NEG cells; these cells lost their ability to respond to stimulation by endothelin. We analyzed the effects of endothelin receptor antagonists alone or in combination with rapamycin, an mTOR inhibitor, on proliferation and migration of LAM cells. Rapamycin treatment of TSC2NEG cells significantly reduced cell proliferation or migration, while none of the tested inhibitors of EDN receptors impaired these functions. We showed that TSC2NEG cells have acquired a transformed phenotype as showed by their ability to grow as spheroids in semi-solid medium and that unlike endothelin receptors antagonists, rapamycin reduced anchorage-independent cell growth and prevented expansion of TSC2NEG spheroids.Chebib, Nader, et al. "Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration." Scientific reports 8.1 (2018): 14698.
This kit is easy to use and provides a high quality yield.
- M.B. (Syracuse University)
“I was very impressed with the purity of the DNA.”
- C.V. (UCLA)
“Improved yield than Bioline and Qiagen Kits.”
- F.C. (Manchester Metropolitan University)